Yes, it suggests that it was just highly improbable that the study could achieve superiority. What happened was that it failed the inferiority test at some preset level. However without knowing the details of where that level was set or what the level achieved actually was, its impossible to say more. I don't really agree with you that it was necessarily showing significant superiority at the 45% interim analysis. It might have only just scraped past the inferiority test at that point.
I suspect that Novartis won't allow publication of any details until they complete their analysis, if in fact it ever gets published.
Novartis deal on the rocks, page-139
-
- There are more pages in this discussion • 109 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |